Liminal BioSciences Announces FDA Approval for its Biologics License Application for Ryplazim (plasminogen, human-tvmh)
LAVAL, QC and CAMBRIDGE, England, June 4, 2021 /PRNewswire/ -- Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company") announced today that the U.S. Food & Drug Administration